- Roche Holdings AG (OTC:RHHBY) announced that updated clinical data for its CD20xCD3 T-cell engaging bispecific antibodies, including five oral presentations, were presented at the American Society of Hematology Annual Meeting & Exposition.
- Updated data from the pivotal phase 2 NP30179 study in relapsed or refractory large B-cell lymphoma (R/R LBCL) showed glofitamab given as a fixed course induced early and durable responses that were maintained beyond the end of treatment.
- Most patients who had achieved a complete response experienced durable responses, with a median CR follow-up from the end of treatment of 11.5 months.
- Twelve months after the end of treatment with glofitamab, 61% of patients maintained a CR, 92.6% remained progression-free, and only one patient (n=1/44) experienced disease progression.
- An updated analysis from the pivotal phase 2 GO29781 study of Lunsumio in people with R/R follicular lymphoma FL who had received two or more prior therapies showed that 60.0% achieved a CR and 77.8% achieved an objective response at a median follow-up of 28.3 months.
- After 24 months of achieving a CR, 62.7% of patients remained in remission. Overall, 48.3% of patients remained progression-free.
- Price Action: RHHBY shares are down 0.27% at $40.41 on the last check Monday.
Affirm Expands To Self-Checkout At Walmart Stores; This Holiday Shopping Season, Eligible Consumers Can Pay Over Time With Affirm At Over 4,500 Walmart Stores In The U.S.
This holiday shopping season, eligible consumers can pay over time with Affirm at over 4,500 Walmart stores in the U.S.Affirm (NASDAQ:AFRM), the payment network that empowers consumers and helps merchants drive growth,
